JB

Jayameetbhai Bhamushankar Mehta

Active Director Director DIN 10533215
DIN 10533215 First appointment Mar 2024 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Mar 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Jayameetbhai Bhamushankar Mehta

Data last updated:

Jayameetbhai Bhamushankar Mehta is a Director at Pantheonmeds Pharmaceutical Private Limited (since 2024). The company operates in Pharma.

DIN 10533215
Primary Designation Director
Industry Pharma
First Appointment 03 Mar 2024
Oldest Company Age 2 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director03 Mar 20242024Active

Board colleagues of Jayameetbhai Bhamushankar Mehta

Directorship timeline

Open interactive timeline →
Pantheonmeds Pharmaceutical Private Limited
Premium access

Shareholding and investment profile for Jayameetbhai Bhamushankar Mehta

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Jayameetbhai Bhamushankar Mehta

Jayameetbhai Bhamushankar Mehta currently holds 1 directorship: Pantheonmeds Pharmaceutical Private Limited (Director, since 03 Mar 2024).

Jayameetbhai Bhamushankar Mehta was first appointed on 03 Mar 2024 as Director at Pantheonmeds Pharmaceutical Private Limited.

The current boards of Jayameetbhai Bhamushankar Mehta's companies include Dipak Bhima Dangar (Pantheonmeds Pharmaceutical Private Limited), Nishant Bhanubhai Maheta (Pantheonmeds Pharmaceutical Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available